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Treatment of small cell lung cancer (SCLC) is probably one of the
great challenges of medical oncology owing to an increasing
incidence in both men and women and a poor prognosis despite
chemosensitivity (Ianuizzi and Scoggin, 1986; Hansen and
Kristjansen, 1991). Serum markers have been proposed as a help
in the management of SCLC during chemotherapy. In this setting,
the most-established serum marker is the gamma–gamma isomer
of a glycolytic enzyme referred to as neuron specific enolase
(NSE) (Cooper et al; 1985; Jorgensen et al, 1989). High pretreat-
ment levels of serum NSE are an indicator of extended tumour
mass and poor prognosis (Cooper et al; 1985). Recently, two
tumour markers detecting cytokeratins in the serum were proposed
in the management of lung cancer (mainly non-SCLC): CYFRA
21-1 (Pujol et al, 1993, 1996a; Van Der Gaast et al, 1994), a
cytokeratin fragment recognized by KS 19-1 and BM 19-21 anti-
bodies, and TPS (Pujol et al, 1994), the specific M3 epitope of the
tissue polypeptide antigen. It has been shown that a high
pretherapeutic level of CYFRA 21-1 or TPS is an independent
determinant of survival.
The prognostic value of the initial (pre-therapeutic) level of
tumour markers is, therefore, well-established (Jorgensen et al,
1989; Pujol et al, 1993, 1994). However this level is not defini-
tively fixed inasmuch as reversible states might be observed
during therapy. Thus, the management of patients presenting
SCLC might be helped by knowing the signification of each state
(level) separately. These reversible variables are not only the
serum level of markers (over or under the cut-off value) but also
the response status of the disease as analysed using the World
Health Organization (WHO) criteria (World Health Organization,
1979) (complete responders, partial responders and non-respon-
ders). For instance, it has been demonstrated that patients who
benefit most from chemotherapy are those for whom a dramatic
decrease in serum NSE level is observed (Jorgensen et al, 1989).
However, the significance of this decrease in relation to patient
outcome is unknown and thus is of poor clinical use as yet.
The homogeneous Markov model is a tool able to evaluate the
transition intensities between states which are: a high level of
marker (over cut-off level), a low level of marker and, finally,
Markov model and markers of small cell lung cancer:
assessing the influence of reversible serum NSE,
CYFRA 21-1 and TPS levels on prognosis
J-M Boher1, J-L Pujol1,2, J Grenier3 and J-P Daurès1
1Département de Biostatistiques Epidemiologie et Recherche Clinique, Institut Universitaire de Recherche Clinique, Rue de la Cardonille, 34093 Montpellier
Cedex 5, France; 2Département des Maladies Respiratories, Centre Hospitalier Universitaire de Montpellier, Hôpital Arnaud de Villeneuve, 34295 Montpellier
Cedex, France; and 3Centre Régional de Lutte contre le Cancer, Laboratoire de Radio-Analyses, 34094 Montpellier Cedex, France
Summary High serum NSE and advanced tumour stage are well-known negative prognostic determinants of small cell lung cancer (SCLC)
when observed at presentation. However, such variables are reversible disease indicators as they can change during the course of therapy.
The relationship between risk of death and marker level and disease state during treatment of SCLC chemotherapy is not known. A total of
52 patients with SCLC were followed during cisplatin-based chemotherapy (the median number of tumour status and marker level
assessments was 4). The time-homogeneous Markov model was used in order to analyse separately the prognostic significance of change in
the state of the serum marker level (NSE, CYFRA 21-1, TPS) or the change in tumour status. In this model, transition rate intensities were
analysed according to three different states: alive with low marker level (state 0), alive with high marker level (state 1) and dead (absorbing
state). The model analysing NSE levels showed that the mean time to move out of state ‘high marker level’ was short (123 days). There was
a 44% probability of the opposite reversible state ‘low marker level’ being reached, which demonstrated the reversible property of the state
‘high marker level’. The relative risk of death from this state ‘high marker level’ was about 2.24 times greater in comparison with that of state
0 ‘low marker level’ (Wald’s test; P < 0.01). For patients in state ‘high marker level’ at time of sampling, the probability of death increased
dramatically, a transition explaining the rapid decrease in the probability of remaining stationary at this state. However, a non-nil probability to
change from state 1 ‘high marker level’ to the opposite transient level, state 0 ‘low marker level’, was observed suggesting that, however
infrequently, patients in state 1 ‘high marker level’ might still return to state 0 ‘low marker level’. Almost similar conclusions can be drawn
regarding the three-state model constructed using the tumour response status. For the two cytokeratin markers, the Markov model suggests
the lack of a true reversible property of these variables as there was only a very weak probability of a patient returning to state ‘low marker
level’ once having entered state ‘high marker level’. In conclusion, The Markov model suggests that the observation of an increase in serum
NSE level or a lack of response of the disease at any time during follow-up (according to the homogeneous assumption) was strongly
associated with a worse prognosis but that the reversion to a low mortality risk state remains possible.
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Correspondence to: JL Pujoldeath (Kay, 1986). Thus, this model allows the analysis of the rela-
tionship between the level of the marker and the outcome by using
serial tumour marker assessments. It makes it possible to ascertain
that a high level of marker is also an indicator of poor prognosis
regardless of the time of transition from a low level to a high level.
Thus, the Markov model assumption is that prognosis depends on
past observations only through the last observed level of the
marker (Kay, 1986). This assumption seems realistic in the case of
SCLC. The present study deals with applying the homogeneous
Markov model analysis to NSE, CYFRA 21-1, TPS serum levels
and tumour response status on the one hand and their relationship
with survival on the other. This study produced different transition
intensities, particularly the instantaneous mortality hazard, of each
marker, level by level.
PATIENTS AND METHODS
Patients
Fifty-two consecutive patients with pathologically confirmed
SCLC as defined by the WHO classification (World Health
Organization, 1982) were prospectively entered in the study.
Performance status (PS) was estimated according to the Eastern
Cooperative Oncology Group (ECOG) and the percentage of
weight loss during the previous 4 months was recorded. Staging
was carried out by exhaustive procedures according to the 4th
edition of the Union Internationale Contre le Cancer (UICC)
tumour node metastases (TNM) classification (Sobin et al, 1987),
the American Thoracic Society map of regional pulmonary nodes
(Tisi et al, 1982) and Mountain’s stage grouping. In order to estab-
lish the disease stage, the following investigations were applied:
clinical examination, standard chest roentgenography, computed
tomographic (CT) scan of chest, upper abdomen and brain, fibre-
optic bronchoscopy, and bone scanning. This staging procedure
resulted in the classification of the disease into one of the two
following groups: (1) limited disease, a disease confined to one
hemithorax including mediastinal lymph nodes and/or supraclav-
icular lymph nodes; (2) extensive disease, defined as having the
opposite criteria to limited disease. Patients with malignant pleural
effusion were considered as having extensive disease. There were
27 (52%) patients suffering from limited disease and 25 from
extensive disease.
The following pretreatment characteristics were also recorded:
weight loss during the 3 months preceding the diagnosis, serum
sodium (lower normal value 135 mmol l-1), serum albumin (lower
normal value 32 g l–1), lactate dehydrogenase (LDH, upper normal
value 600 U l–1), alkaline phosphatase (upper normal value
125 U l–1), blood leukocyte count (upper normal value 10 000 ml–1)
and performance status according the ECOG scale (63% had a PS
0 or 1 and 19 a PS 2). The complete panel of serum markers tested
is described later.
Sampling method
A blood sample was taken from each patient at presentation, and
then at each other cycle visit (every 7 weeks). Following the treat-
ment period, serum samplings were done during routine 3-monthly
follow-up visits which consisted of a medical examination, chest
X-ray and tumour marker assessment. The median number of
marker level assessments was 4. However, due to the behaviour of
SCLC (frequent relapses requiring readmission or new treatments,
readmission for toxic events, etc.) some patients did not have
samples taken as regularly as indicated above. The serum was sepa-
rated and stored at – 190°C until tested. Serums were assayed blind
of any clinical information; thus treatment decisions were taken
without knowledge of serum marker levels.
Biochemical measurements
CYFRA 21-1TM is a cytokeratin fragment 19 recognized by KS 19-
1 and BM 19–21 monoclonal antibodies [mAb] (Centocor
Diagnostics, Malvern, PA, USA and Cis Biointernational,
Gif/Yvette, France). This solid phase immuno-radiometric assay
based on the two-site sandwich method has been previously
decribed in detail (Pujol et al, 1993). Briefly, in this method the
cytokeratin 19 is recognized by two mouse MoAb, KS 19-1 and
BM 19–21, directed against two different epitopes of a fragment of
cytokeratin subunit 19, which is referred to as serum CYFRA 21-
1. The calculated concentration of cytokeratin 19 is expressed in
ng ml–1.
TPSTM (BEKI Diagnostics AB, Bromma, Sweden) which
detects the specific M3 epitope of the tissue polypeptide antigen
(TPA) has been described extensively (Pujol et al, 1994). Briefly,
TPS is a two-site immunoradiometric assay using two types of
antibodies in excess: polyclonal anti-TPA horse antibodies bound
to plastic beads and 125I labelled mouse IgGl kappa anti-M3
MoAb. The latter antibody is raised against the M3 epitope of TPA
which is specifically expressed by proliferating cells. The method
of TPS titration has been described at length. The M3 concentra-
tion of the sample was determined using the results of construction
of the standard curve and was expressed in U l–1.
Serum NSE was measured by a radioimmunoassay (Cis
Biointernational, Gif/Yvette, France). The respective upper limits
of normal values were 3.6 ng ml–1, 12.5 ng ml–1 and 140 U l–1 for
serum CYFRA 21-1, serum NSE and serum TPS, respectively.
These cut-off values have been predifined in previously published
studies (Cooper et al, 1985; Pujol et al, 1993, 1994). They corre-
spond to the 90–95% specificity as determined in patients with
nonmalignant pulmonary disease.
Treatment
For patients with extensive SCLC disease, chemotherapy consisted
of a cyclophosphamide–4¢-epidoxorubicin–etoposide and cisplatin
combination given for a minimum of four cycles. Thoracic radio-
therapy and prophylactic cranial irradiation were applied to patients
with a complete response and to patients with partial response if
residual tumour was confined to the chest at the end of the six-cycle
chemotherapy programme. Treatment in patients with limited
disease consisted of the same chemotherapy combination alter-
nating with thoracic radiotherapy after cycle 2. Three courses of
radiotherapy were given as a split course modality with concomi-
tant prophylactic cranial irradiation during the third course. After
the sixth cycle, chemotherapy was maintained only in those
patients with residual disease on CT-scan whatever the prethera-
peutic tumour status was.
Response assessment
Indicator lesions were predefined at time of inclusion on
CT-scan documents. Restaging was done at the end of the
induction chemotherapy and every other cycle, thereafter WHO
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Health Organization, 1979).
Our response assessment procedure has been described in detail
(Pujol et al, 1996b). Briefly, tumour response for the chest, the
liver, the adrenal glands and the brain were analysed by CT-scan
assessing two-dimensional, measurable indicator lesions.
Calculation of response rate was done as follows:
response (%) =
(inital D ´ initial D¢) – (final D ´ final D¢)
´ 100,
(initial D ´ initial D¢)
where D and D¢ are the longest perpendicular diameters of the indi-
cator lesions. A complete response was defined as the complete
disappearance of all lesions; a partial response was defined as equal
to, or greater than, a 50% reduction in the product of the two
longest perpendicular diameters of the indicator lesions for measur-
able tumours, or an improvement equal to or greater than 50% for
evaluable-only tumours. Stable disease was defined as a less than
50% reduction and a less than 25% increase in this product. Finally,
progressive disease was defined as equal to or greater than a 25%
increase in this product, or appearance of new lesions. As published
recently (Pujol et al, 1996b), the definition of a complete response
included fibreoptic bronchoscopy data: a complete response was
considered as a complete disappearance of all endo-bronchial
lesion, or a non-specific scar, such as a minimal obstruction of a
segmental bronchus with a negative bronchial re-biopsy.
Lesions identified by bone scanning were considered as evalu-
able-only. Tumour response was assessed according to the WHO
criteria: disappearance of all lesions lasting for a minimum of 4
weeks resulted in a complete response. Appearance of new lesions
was considered as progression. Other cases were considered as
stable disease.
Finally, we defined the overall response as follows: where
multiple indicator lesions were assessed, all individual results
were taken into account. When discrepancies were observed in
results obtained by different measurable indicator lesions, the
worst results were considered overall according to the WHO
recommendations (World Health Organization, 1979). On the
other hand, a stable result obtained by assessing an evaluable
lesion did not detract from a partial response in measurable lesions
but reduced a complete response in measurable lesions to partial
response overall. For instance, if the restaging demonstrated a
partial response for a measurable indicator lesion on CT scan and a
stable disease for bone metastasis evaluated by bone scan, the
overall response was classified as a partial response. If in the total
of responses per organ site there were equal or greater numbers of
complete plus partial responses than of no change, the overall
response was partial.
Description of homogeneous Markov model
With conventional prognostic studies, patients are classified into
different subgroups according to the value of a given variable
recorded at time of origin of the study. Such a variable is referred
to as a time-independent variable. This is the case with most of
the pretreatment variables known to influence significantly the
outcome of SCLC patients, e.g. metastatic status or performance
status. Survival analysis consists of the calculation of the risk of
death which affects a patient classified in a given subgroup. On the
other hand, the Markov model allows the analysis of the prog-
nostic influence by calculating a hazard ratio of a variable which
can take different values for a given patient over a period of time.
This type of variable is referred to as a time-dependent (or
reversible) variable. The level of a tumour marker generally
belongs to this category. In this model, for each evaluation the
patients are classified into one of the following three states: dead
(state 2, absorbing state as there is no transition from it), normal
level of the marker (state 0) and high level of the marker (state 1).
The last two states are called transient states as a given patient can
move from the normal to the high level and conversely.
Transition intensities which link the transient states are conven-
tionally denoted by l01 (transition from normal to high level state)
and l10 (transition from a high to a low level state) whereas the risk
of death is denoted by m0 (risk of death from a normal level) and m1
(risk of death from a high level). The stochastic structure of the
Markov model is specified by its transition intensities according to
the formula defined in the appendix (Kalbfleish and Prentice,
1980; Kay, 1986; Grüger et al, 1991).
Inasmuch as none of these transition intensities are time-depen-
dent, the model is referred to as a time-homogeneous Markov
model. The matrix of transition intensities is defined in the
Appendix. The respective values of the states 0 and 1 for each
analysed, reversible variable are described in Table 1. In addition
to the usual serum NSE threshold level of 12.5 ng ml–1, a higher
threshold, 25 ng ml–1, was tested in order to assess the validity of
the model.
Estimation method
We considered that the changes in marker levels were not
concomitant with the sampling time. The hypothesis was that this
change could have occurred at any time during the time interval
between two serum tests. To ascertain the homogeneous assump-
tion of the Markov model the transition intensities were analysed
during the period following the induction therapy. Therefore, the
chosen date of origin was the end of the second chemotherapy
cycle. A detailed estimation method is reported in the Appendix.
Test hypothesis
In order to test whether or not survival depends on the marker levels
we used the likelihood ratio statistic LR = 2log L(l01, l10, m0, m1)/
L(l01, l10, m0, m0), which under H0: m0 = m1 has an approximatively
c2 distribution with one degree of freedom (Kay, 1986; Gentleman
et al, 1994).
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Table 1 Cut-off level for each marker analysed
State 0 State 1
Serum NSEa ≤ 12.5 ng ml–1 > 12.5 ng ml–1
≤ 25 ng ml–1 > 25 ng ml–1
Serum CYFRA 21-1 ≤ 3.6 ng ml–1 > 3.6 ng ml–1
Serum TPS ≤ 140 U l–1 > 140 U l–1
Response statusb CR or PR NC
CR, complete response; PR, partial response; NC, no change; PD,
progressive disease. aIn addition to the usual serum NSE threshold level of
12.5 ng ml–1, a higher threshold, 25 ng ml–1 was tested. bFor the model using
the response status, the absorbing state (state 2) was considered as either a
progressive disease or death.Prognosis
The main purpose was to assess the respective effect of a high and
a low marker level on prognosis at any sampling time t. This can
be done via the transition matrix (Kay, 1986) defined by P(s — t) =
eQ(s—t) and estimated by ˆ P(s — t) = eˆ Q(s—t). This matrix gives the prob-
abilities of being in one of the states described in Figure 1 at time
s, taking into account the state occupied at time t. According to the
homogeneity assumption, the h, k entry Phk(d) is also the proba-
bility of being in state k, providing that the patient was in state h, d
weeks previously (d might represent the time elapsed since the last
sampling). Thus Phk(d) is an indicator of prognosis for the future
outcome.
Adjustment of Markov model using co-variables
In addition to the serum marker titrations we also recorded the
status of the patient regarding other pre-treatment co-variables
such as sex, performance status, nodal status, etc. Having obtained
the Markov model describing the transition intensities linking the
different states of a patient according to the level of the marker, the
question is whether or not transition intensities are influenced
by these putative co-variables. To answer this specific question
the Markov model was adjusted using a stepwise regression
(Kalbfleish and Lawless, 1985). In this procedure, co-variables
were entered and removed according to the benefit or loss they
brought to the likelihood as assessed by a likelihood ratio statistic.
This process allowed all confounding variables to be removed
from the model according to their correlation with the selected set
of regression in the final model. By the end of this regression
analysis, the transition intensity and the variables which statisti-
cally influence the transition have been described.
RESULTS
Three-state Markov model analysis using tumour
markers and response status
In Table 2 the observed transitions are described. Table 3 shows
the four Markov three-state models and the corresponding transi-
tion rate parameters (transition intensities and mortality hazards)
of each reversible variable. Definition of state of disease and
transition rates are shown in Figure 1.
The most striking model is the one using the 12.5 ng ml–1
threshold for serum NSE. The mean time to move out of state 1
(high NSE level) was 1/(l10 + m1) = 123 days. At that time, the
probability that the opposite reversible state (alive with low NSE
level) was reached, was l10 /(l10 + m1) = 44%, demonstrating the
reversible property of state 1; on the other hand, the probability
that the patient died was m1/(l10 + m1) = 56%. The mean time to
move out of state 0 (low NSE level) was 238 days. The relative
risk of death for state 1 (namely mortality hazard m1) was about
2.24 times greater in comparison with that for state 0 (mortality
hazard m0). In this setting, the likelihood ratio statistic demon-
strated that this difference was significant. Thus, a patient in state
1 (high NSE level) was at high risk of death. This suggests that the
observation of an increase of NSE at any time during treatment
(according to the homogeneous assumption) was strongly associ-
ated with a worse prognosis. The respective transition parameters
obtained with the 12.5 and 25 ng ml–1 thresholds suggested a
gradual increase in risk inasmuch as the m1/m0 ratio was 2.24 for
the lower threshold and 4.67 for the higher.
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state 0 state 1
death
l01
l10
m0 m1
Figure 1 State diagram of the homogeneous Markov model. States 0 and 1
are defined as the respective levels of the reversible variable (see Table 1).
State 2 is the absorbing state (death). The possible transitions are shown by
arrows. Transition between reversible states are characterized by the l
transition intensity. Otherwise, instantaneous mortality hazards are
characterized by m
Table 2 Number of observed transitions
Model From state To state
0 1 2 Censored
NSE (12.5 ng ml–1)0 – 1 8 1 7 8
1 20 – 26 1
CYFRA 21-1 0 – 5 32 8
10 –1 0 1
TPS 0 – 8 28 8
13 –1 5 1
Tumour status 0 – 0 30 7
11 3 – 7 0
Table 3 Transition intensities and mortality hazard (standard errors) among states for each marker studieda
Parameters NSE 12.5 ng ml–1 NSE 25 ng ml–1 CYFRA21-1 TPS Tumour response
l01 2.166 (0.512) 0.56 (0.21) 0.399 (0.178) 0.687 (0.243) b
l10 3.521 (0.793) 2.08 (1.21) c 1.277 (0.740) 11.631 (0.335)
m0 2.046 (0.498) 2.23 (0.42) 2.552 (0.452) 2.405 (0.455) 3.054 (0.056)
m1 4.577 (0.907) 10.42 (2.77) 7.872 (2.548) 6.385 (1.680) 6.263 (0.242)
LR statistic 6.688 (P < 0.01) 18.11 (P < 0.001) 7.578 (P < 0.01) 7.982 (P < 0.005) 2.1 (P = 0.12)
LR, likelihood ratio. aThe table entries are the transition intensities and mortality multiplied by 103. bWe did not estimate l01 transition intensity for tumour
response owing to the lack of observed transition from state 0 to state 1. cWe did not estimate l10 transition intensity for CYFRA 21-1 owing to the lack of
observed transition from state 1 to state 0.Markov model and marker of lung cancer 1423
British Journal of Cancer (1999) 79(9/10), 1419–1427 © Cancer Research Campaign 1999
1.0
0.8
0.6
0.4
0.2
0.0
A
t t+20 t+140 t+180 t+60 t+100
d in weeks
1.0
0.8
0.6
0.4
0.2
0.0
B
t t+20 t+140 t+180 t+60 t+100
d in weeks
1.0
0.8
0.6
0.4
0.2
0.0
A
t t+20 t+140 t+180 t+60 t+100
d in weeks
1.0
0.8
0.6
0.4
0.2
0.0
B
t t+20 t+140 t+180 t+60 t+100
d in weeks
1.0
0.8
0.6
0.4
0.2
0.0
A
t t+20 t+140 t+180 t+60 t+100
d in weeks
1.0
0.8
0.6
0.4
0.2
0.0
B
t t+20 t+140 t+180 t+60 t+100
d in weeks
1.0
0.8
0.6
0.4
0.2
0.0
A
t t+20 t+140 t+180 t+60 t+100
d in weeks
1.0
0.8
0.6
0.4
0.2
0.0
B
t t+20 t+140 t+180 t+60 t+100
d in weeks
Figure 2 Effect of serum NSE level on the probability that can be
prognosed d weeks after sampling at time t (taking into account the
12.5 ng ml–1 threshold). Each curve represents the probability at time t + d
weeks: thick line, probability of death; thin line, probability of remaining in the
same reversible state; dotted line, probability of changing to the opposite
level. (A) for a patient in state 0 at time t (B) for a patient in state 1 at time t Figure 4 Effect of serum CYFRA 21-1 level on the probability that can be
prognosed d weeks after sampling at time t. Each curve represents the
probability at time t + d weeks: thick line probability of death; thin line,
probability of remaining in the same reversible state; dotted line, probability
of changing to the opposite level. (A) for a patient in state 0 at time t, (B) for
a patient in state 1 at time t
Figure 3 Effect of tumour response status level on the probability that can
be prognosed d weeks after sampling at time t. Each curve represents the
probability at time t + d weeks: thick line, probability of death; thin line,
probability of remaining in the same reversible state; dotted line, probability
of changing to the opposite level. (A) for a patient in state 0 at time t, (B) for
a patient in state 1 at time t
Figure 5 Effect of serum TPS level on the probability that can be
prognosed d weeks after sampling at time t. Each curve represents the
probability at time t + d weeks: thick line, probability of death; thin line,
probability of remaining in the same reversible state; dotted line, probability
of changing to the opposite level. (A) for a patient in state 0 at time t, (B) for
a patient in state 1 at time tAnalysing CYFRA 21-1, the three-state Markov model again
demonstrated a significant difference in mortality hazards as
patients in state 1 (alive with a high CYFRA 21-1 level) had an
instantaneous risk of death treble that of patients in state 0. Again
the likelihood statistic was significant. However, using the well-
established 3.6 ng ml–1 CYFRA 21-1 threshold, the state of the
marker did not demonstrate a reversible property: the mean time to
move out of state 1 was 128 days. This movement only depended
on the probability of death. In other words, the probability was
zero of a patient returning to state 0 having once entered state 1.
The mean time to move out of state 0 was 344 days. Although non-
nil, the probability of the transition reaching state 1 was only 14%
and thus the probability that transition was due to death of the
patient was 86%.
Transition parameters of TPS also demonstrated a higher
mortality hazard for patients in state 1 (alive with high TPS level)
in comparison with those patients in state 0 (likelihood ratio test
P < 0.005). Similar to CYFRA 21-1, passages from state 0 to 1, and
conversely, were of low intensity. Thus, the probability of a patient
returning to state 0, having once reached state 1, was low. This
weakens the use of TPS as a reversible tumour marker in SCLC.
Finally, the three-state Markov model analysing tumour
response status considered responder patients as occupying state 0,
whereas non-responders occupied state 1 and patients with either a
progressive disease and patients who died occupied state 2
(absorbing state). Mortality hazards differed with patients in state
1 having the higher risk. The relative risk of death for state 1
(namely mortality hazard m1) was about 2.1. However, in this
setting, the likelihood ratio statistic did not demonstrate statistical
significance. This was probably due to the low number of transi-
tions (Table 2). There was no true reversible property of states 0
and 1 as the probability l10 was 0.
Prognostication of outcome using the data obtained
from Markov models
As a complement to the instantaneous transition rates, inferent
statistics produced the probability functions charted in Figures 2 to
5 taking into account the state of the marker at time t. Each curve
represents the probability function which prognosticates d weeks
after sampling the occupied state (opposite transient state, death or
stationary position in the same state). As shown in Figure 2
regarding the three-state Markov model analysing the NSE level,
these probabilities differed according to the state occupied at time
t. Where the patient was in state 0 (alive with low NSE level) at
time t, the probability of being stationary at this state decreased
slowly with time, whereas the probability of death progressively
increased. The lowest probability was the transition to state 1.
Graphically, this last transition appeared to occur mainly during
the first weeks following the sampling whereas, after this time,
patients were almost exclusively exposed to the risk of death as the
only possible transition. Conversely, when one considers a patient
in state 1 at time t, the probability of death (1 — probability of
survival) dramatically increased, a transition which explains the
rapid decrease of the probability of remaining stationary at state 1.
However, a non-nil probability of changing from state 1 to the
opposite transient level state 0 was observed suggesting that,
however infrequently, patients in state 1 might still return to state
0. Similar conclusions can be drawn regarding the three-state
model constructed using the tumour response status (Figure 3).
Less informative are the probability functions constructed using
the three-state Markov model analysing CYFRA 21-1 (Figure 4).
Whatever the considered state occupied at time t the probability of
death was roughly equal to 1 — the probability of remaining
stationary at the state occupied at time t owing to the small number
of transitions observed between transient states. The mean
survival was therefore reached when the probability function of
being in the same state decreased to 50%. Again, this demon-
strated the lack of true reversible status of CYFRA 21-1 in SCLC.
Almost similar conclusions can be drawn regarding the three-state
model constructed using TPS levels (Figure 5).
Adjustment of the Markov model using co-variables
As the aim of this study was to investigate the prognostic value of
markers, only the Markov model using the serum NSE titrations
was adjusted as NSE was the only model of interest in this setting
(using the 12.5 ng ml–1 threshold). Stepwise regression analysis
demonstrated that the m1 transition intensity was significantly
influenced by the nodal status co-variable inasmuch as patients
with a positive mediastinal nodal status have a death hazard ratio
from a state ‘high serum NSE level’ of 3.6. On the other hand,
patients over 63 years proved to have a death hazard ratio of 2.5
from a state of ‘normal serum NSE level’ (m0; Table 4).
DISCUSSION
Among the different clinical applications of tumour markers in
human malignancies, prognostication of the outcome might be
regarded as an important issue (Bates, 1991). For lung cancer, deci-
sions regarding therapy are influenced not only by pretreatment
prognostic determinants (tumour status, stage of the disease,
histology) but also by variables occurring during the course of the
disease, for instance, the appearance of new lesions or occurrence
of life-threatening toxic events (Kay, 1986; Andersen et al, 1991).
The pretreatment value of NSE has been demonstrated as being a
prognostic determinant in SCLC (Cooper et al, 1985). Patients with
a high serum NSE level at time of diagnosis prove to have a shorter
survival than patients with a serum NSE equal to or less than the
cut-off value. These results, together with data produced by other
studies for larger populations, suggest that a patient with lung
cancer associated with a high serum NSE level is at higher risk of
death. The question remains as to the clinical use of such an obser-
vation. From the research point of view, the precise characteriza-
tion of prognostic factors is important when analysing survival data
produced, for instance, by two different treatments. From a patient-
by-patient point of view, however, awareness of baseline prog-
nostic variables, except stage of disease, might be considered as a
secondary end-point because it does not influence treatment deci-
sion, namely chemotherapy. In addition, variables such as tumour
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Table 4 Hazard ratio for co-variables influencing the transition intensities of
the Markov model constructed using the NSE level (threshold 12.5 ng ml–1)
Variables Transitions Hazard ratio Asymptotic 95% CI P-value
Sex l01 5.13 [– 1.27; 11.53] 0.021
LDH l01 0.16 [– 0.16; 0.48] 0.021
T status l01 0.31 [– 0.02; 0.63] 0.033
Age m02 3.24 [0.01; 6.47] 0.017
N l10 3.61 [0.26; 6.96] 0.005
N m12 2.53 [0.41; 4.64] 0.029marker levels or tumour status are not definitively fixed at time of
presentation and changes in the level might occur as a result of both
the course of the disease and the effect of therapy. This is not
predicted by the classical Cox’s model (Cox, 1972).
Different methods have been proposed in order to define the
specific clinical effect of the change in a marker level during
therapy of SCLC. One of them consisted of analysing concordance
between modifications of marker level and modifications of
tumour status. Several studies have observed similar behaviour
of tumour mass and NSE level during chemotherapy of SCLC
(Cooper et al, 1985; Jorgensen et al, 1988). It has been demon-
strated that the serum NSE level decreases under cut-off value
at the time when tumour response is demonstrated by tumour
measurement of indicator lesions. Three comments might be
raised in analysing such data: first, if the biological decrease is
concordant with the tumour response assessment, the former para-
meter might be futile as the second is required according to
the World Health Organization Recommendations in Reporting
Results of Cancer Treatment. Secondly, some patients have a
persistent high serum NSE level although they benefited from a
tumour response; whether or not this condition is different from
the general one (concordant decrease of NSE level and tumour
mass) is unknown. Third, the concomitant analysis of tumour
marker level and tumour mass does not answer the main question
regarding the relationship between kinetics of reversible disease
indicators and survival.
The Cox’s model method has been extended to the analysis of
time-dependent covariates, i.e. reversible variables (Andersen et al,
1991). Unlike the classical Cox’s model which analyses variables
definitively fixed at the time of origin (Cox, 1972), this method
considers that a patient could move from one stratum to another,
according to the value of the time-dependent co-variable. It allows
the calculation of the death risk linked to the strata but does not
predict the changes of the time-dependent variable as a function of
time. In other words, it gives prognostic information stratum-by-
stratum but no information about the probabilities of passage from
one state to the other. In addition, tumour markers or tumour disease
status are analysed only at baseline time, and then at rather infrequent
follow-up times, due to the nature of the disease. Thus, the analysis of
such an incomplete observation in Cox’s model might be hazardous.
On the other hand, the three-state Markov model, as described in this
paper, allows an estimation of probability for a patient to be in
various states, even in the case where there is incomplete information
regarding the reversible disease indicators (Gentleman et al, 1994).
In our study we analysed the three-state Markov model of tumour
response assessment and three different tumour markers. Patients
have been studied longitudinally. They all received a cisplatin-based
chemotherapy. The application here of the Markov model using
marker serum levels in SCLC followed the methodology proposed
by Kay (1986) in the setting of Markov analysis of a-foeto-protein
in hepatocellular carcinoma. In SCLC, the homogeneous Markov
assumption is supported by the short survival with high rate of
transitions from state to state occurring early after diagnosis, even
during chemotherapy. Thus, one may assume that the Markov model
is homogeneous. The validity of the model is also suggested by the
increase in risk m1/m0 observed when a higher serum NSE cut-off
level is chosen. Using the Markov model to analyse CYFRA 21-1 or
TPS allows two conclusions: first, the mortality hazard for a patient
who has an elevated serum cytokeratin level is significantly higher
when compared with one of the patients with a low cytokeratin
level. Second, the probabilities of transition from one state to the
other (high or low serum cytokeratin level) are low, particularly in
the case of CYFRA 21-1. Thus, it does not seem useful to make
serial measurements of these markers during treatment and follow-
up of SCLC as the essential prognostic information lies in the base-
line titration with almost no change in state thereafter.
Conversely, the three-state Markov models of serum NSE and
tumour response assessment are informative about the possible use
of these reversible variables. If one considers a patient with a high
NSE level at any time during the treatment course three indications
can be found: the patient is at higher risk of death in comparison
with the opposite transient level (serum NSE less than cut-off
value); the mean time to move out of this state is short; the risk of
death represents the main explanation for this instability but the
patient still has a good probability (44%) of returning to the lower
risk state. Almost similar observations are made for a patient
disclosing a non-responder disease status. According to the regres-
sion analysis, the hazard ratio of risk of death according to a high or
low level of NSE is influenced by few co-variables, namely nodal
status and age. This suggests the relative independence of the prog-
nostic value of NSE in SCLC and it might justify salvage therapy in
patients who experience either an increase in NSE level or progres-
sion of the disease. The homogeneous assumption of the Markov
model supposed that a patient who enters for the first time an
elevated state at time t has the same prognosis as the one who has
more than one transition in his previous history before entering this
state. From a clinical point of view, this assumption might be real-
istic in the case of SCLC. The validity of the Markov model is based
on the number of transitions (which is comparable to the number of
events) rather than the number of patients. This number is 81 for the
NSE Markov model. However, larger multi-centre populations of
SCLC will be needed in order to confirm the results of our study.
One important remaining question belongs to the relevance of
the observation made using the Markov model in clinical practice.
There is, currently, a hope that new drugs such as topoisomerase I
inhibitors and taxanes might be active treatments for patients who
relapse from SCLC and were initially sensitive to more conven-
tional chemotherapy. Therefore, tools able to monitor correctly the
disease after induction therapy might be required in the near future.
The three-state Markov models analysing serum NSE or tumour
response assessment in SCLC make it possible to define the time
to transition, transition intensities and mortality hazards according
to the different states of these reversible disease indicators.
Markov analysis takes into account the incomplete nature of the
observation of these variables which are not monitored continu-
ously. It therefore confers clinical usefulness on both serum NSE
follow-up and tumour reassessment by measuring their relation-
ship with prognosis.
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APPENDIX
Transition intensities which define the stochastic
structure of the Markov model
Matrix of transition intensities
Q =(
–(l01 + m0) l01 m0)
l10 –(l10 + m1) m1
00 0
Estimation method of the Markov model
If M referred to the number of serum assessments, T0, T1, …, TM
referred to the sampling dates and Y0, Y1, …, YM referred to the
respective values of the marker transformed into a binary variable
as described in Table 1. Let T express the minimum time between
survival and censoring date and D express the censoring indicator
(D = 0 for an individual right-censored, D = 1 for an observed
death). Because serum was assayed blind of any clinical informa-
tion, the known or unknown current marker state did not affect the
probability of a patient being tested providing information not yet
recorded. We also assumed that all right-censoring times were
non-informative of the disease progression, i.e. did not depend on
future behaviour.
According to the above assumptions, the likelihood of {M, T0,
Y0, T1, Y1, …, TM, YM, D} is proportional to the likelihood obtained
if the number of serum tests and their times were preplanned. Thus
our sampling plan is called non-informative for the disease
process, according to Kalbfleish and Prentice (1980) and Grüger et
al (1991).
Let L(yi,j;yi,j – 1, ti,j– ti,j – 1) = L (yi,j;ti,j,yi,j — 1, ti,j – 1 …,ti,0,yi,0) express
the probability of making one transition from Yi,j–1 to Yij in time
interval [tij–1, ti,j] given the past. Therefore, each individual record
{mi,ti,0,Yi,0, ti,1, Yi,1, …,ti,mi, Ymi, ti,di} contributes to the likelihood of
the transition intensities (l, m) and is expressed as the following
factor:
The likelihood function for all patients was L(l,m) = Pi Li. The
model parameters (l,  m) were obtained by using the Newton–
Raphson algorithm implemented on BMDP software. The
prechosen starting values of this iterative procedure were the
maximum likelihood estimators when one assumed that the first
recorded time in a new state was the exact time of entry into that
state, i.e. the quotient between mhl, the total number of transitions
from state h to state l and Th, the total time spent in state h by all
individuals,
Given that a homogeneous three-state Markov process is currently
in state h, the time until it moves out of that state has an exponen-
tial distribution with rate (lhl + mh), l ¹ h, therefore the mean time
for moving out of a current state h is 1 / (lhl + mh), l ¹ h and the
probability that the change is to state l equals lhl / (lhl + mh), l ¹ h.
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lhl(t) =lim
D®0
P—[transition h ® l in [t, t + D] ½ state h at t],for h, l = 0, 1 
D or 1, 0,
mh(t) = lim
D®0
P[transition h ® death in [t, t + D] ½ state h at t], for h,  
D l = 1, 2.
j = mi
(yi,j;yi,j — 1, ti,j — ti, j — 1)
(L(xi; yi,mi
, ti,mi
— ti,mi — 1))
di(1 — L(ci; yi,mi
, ti,mi
— ti,mi — 1))1 — d
i.
j = 1
Li = P L
l(0)
hl =
mhl m(0)
h =
mh,3 for h = 0 or 1.
Th Th
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Example of clinical data
Date NSE CYFRA 21-1 TPS Tumour status
(12.5 ng ml–1)
12-12-90 State 1 State 1 State 1 State 1
01-07-91 State 1 State 0 State 1 State 0
01-28-91 State 0 State 0 State 1 State 0
02-21-91 State 0 State 0 State 1 State 0
04-09-91 State 0 State 0 State 1 State 0
07-08-91 State 0 State 0 State 1 State 2
11-05-91 State 1 State 0 State 1 State 2
01-03-92 State 2 State 2 State 2 State 2
A 63-year-old women suffering from extensive-stage SCLC. Despite a chemotherapy-induced complete response lasting 5 months,
relapses occurred and were responsible for death 54 weeks after the diagnosis. For the serum level NSE, the transition from state 0 to
state 1 was an important prognostic determinant.